Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers
Status:
Completed
Trial end date:
2018-11-02
Target enrollment:
Participant gender:
Summary
This is a phase I, double-blind, placebo controlled, parallel group, dose-escalating,
randomised study designed to assess and compare the safety and tolerability, PK, and
immunogenicity of GNbAC1 administered as a single dose at 4 different dose levels of 36, 60,
85 and 110 mg/kg.